ITRM20020049A1 - Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. - Google Patents

Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.

Info

Publication number
ITRM20020049A1
ITRM20020049A1 IT2002RM000049A ITRM20020049A ITRM20020049A1 IT RM20020049 A1 ITRM20020049 A1 IT RM20020049A1 IT 2002RM000049 A IT2002RM000049 A IT 2002RM000049A IT RM20020049 A ITRM20020049 A IT RM20020049A IT RM20020049 A1 ITRM20020049 A1 IT RM20020049A1
Authority
IT
Italy
Prior art keywords
directed against
neutralizing
glycrotein
monoclonal antibodies
human monoclonal
Prior art date
Application number
IT2002RM000049A
Other languages
English (en)
Inventor
Roberto Burioni
Original Assignee
Biostrands S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostrands S R L filed Critical Biostrands S R L
Priority to IT2002RM000049A priority Critical patent/ITRM20020049A1/it
Publication of ITRM20020049A0 publication Critical patent/ITRM20020049A0/it
Priority to EP03705004A priority patent/EP1476468B9/en
Priority to ES03705004T priority patent/ES2314179T3/es
Priority to EA200401081A priority patent/EA009861B1/ru
Priority to CA2474801A priority patent/CA2474801C/en
Priority to AU2003208000A priority patent/AU2003208000B2/en
Priority to AT03705004T priority patent/ATE407147T1/de
Priority to PCT/IT2003/000032 priority patent/WO2003064473A2/en
Priority to CNA038030926A priority patent/CN1856508A/zh
Priority to RU2004126238/13A priority patent/RU2004126238A/ru
Priority to JP2003564093A priority patent/JP4287280B2/ja
Priority to NZ534922A priority patent/NZ534922A/en
Priority to US10/502,307 priority patent/US20050084845A1/en
Priority to DE60323333T priority patent/DE60323333D1/de
Priority to DK03705004T priority patent/DK1476468T3/da
Priority to KR1020047011208A priority patent/KR101002791B1/ko
Publication of ITRM20020049A1 publication Critical patent/ITRM20020049A1/it
Priority to ZA200406187A priority patent/ZA200406187B/en
Priority to US12/128,344 priority patent/US7727529B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT2002RM000049A 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. ITRM20020049A1 (it)

Priority Applications (18)

Application Number Priority Date Filing Date Title
IT2002RM000049A ITRM20020049A1 (it) 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
KR1020047011208A KR101002791B1 (ko) 2002-01-30 2003-01-29 Ｈｃｖ ｅ2 당단백질을 표적하고 시험관내 중화 활성을보유하는 사람 단클론항체 ｆａｂ 단편
CNA038030926A CN1856508A (zh) 2002-01-30 2003-01-29 针对HCV E2糖蛋白并赋予了体外中和活性的人单克隆抗体Fab片段
JP2003564093A JP4287280B2 (ja) 2002-01-30 2003-01-29 ＨＣＶＥ２グリコプロテインに対して向けられ、ｉｎｖｉｔｒｏ中和活性を有するヒトモノクローナル抗体Ｆａｂ断片
EA200401081A EA009861B1 (ru) 2002-01-30 2003-01-29 Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
CA2474801A CA2474801C (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
AU2003208000A AU2003208000B2 (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity
AT03705004T ATE407147T1 (de) 2002-01-30 2003-01-29 Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
PCT/IT2003/000032 WO2003064473A2 (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
EP03705004A EP1476468B9 (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
RU2004126238/13A RU2004126238A (ru) 2002-01-30 2003-01-29 Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
ES03705004T ES2314179T3 (es) 2002-01-30 2003-01-29 Fragmentos fab de anticuerpo monoclonal humano dirigidos contra la gucoproteina e2 del vhc y que estan dotados de actividad neutralizante in vitro.
NZ534922A NZ534922A (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity
US10/502,307 US20050084845A1 (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
DE60323333T DE60323333D1 (de) 2002-01-30 2003-01-29 Fab-fragmente humaner monoklonaler antikörper mit protein
DK03705004T DK1476468T3 (da) 2002-01-30 2003-01-29 Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet
ZA200406187A ZA200406187B (en) 2002-01-30 2004-08-03 Human monoclonal antibody fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity
US12/128,344 US7727529B2 (en) 2002-01-30 2008-05-28 Human monoclonal antibody Fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002RM000049A ITRM20020049A1 (it) 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.

Publications (2)

Publication Number Publication Date
ITRM20020049A0 ITRM20020049A0 (it) 2002-01-30
ITRM20020049A1 true ITRM20020049A1 (it) 2003-07-30

Family

ID=11456013

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002RM000049A ITRM20020049A1 (it) 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.

Country Status (17)

Country Link
US (2) US20050084845A1 (it)
EP (1) EP1476468B9 (it)
JP (1) JP4287280B2 (it)
KR (1) KR101002791B1 (it)
CN (1) CN1856508A (it)
AT (1) ATE407147T1 (it)
AU (1) AU2003208000B2 (it)
CA (1) CA2474801C (it)
DE (1) DE60323333D1 (it)
DK (1) DK1476468T3 (it)
EA (1) EA009861B1 (it)
ES (1) ES2314179T3 (it)
IT (1) ITRM20020049A1 (it)
NZ (1) NZ534922A (it)
RU (1) RU2004126238A (it)
WO (1) WO2003064473A2 (it)
ZA (1) ZA200406187B (it)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
JP2010519916A (ja) * 2007-03-06 2010-06-10 リボバックス バイオテクノロジーズ ソシエテ アノニム 風疹ウイルスに特異的な抗体
US20100291545A1 (en) 2007-07-25 2010-11-18 Takaji Wakita Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof
TW200940090A (en) * 2007-12-17 2009-10-01 Medical Res Council Technology Hepatitis C virus antibodies
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
WO2010035292A1 (en) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
ITTO20080964A1 (it) * 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
US8592559B2 (en) 2009-10-30 2013-11-26 Toray Industries, Inc. Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof
AU2011223906B2 (en) 2010-03-01 2015-06-25 Vincent Agnello Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients
CN104119436B (zh) * 2013-04-27 2016-12-28 中国科学院上海生命科学研究院 抗丙型肝炎病毒的中和性全人单克隆抗体
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
KR20180001380U (ko) 2016-10-31 2018-05-10 대우조선해양 주식회사 해양구조물의 발로 작동시키는 캡스탄
EP4083211A4 (en) 2019-12-27 2024-07-03 Chiome Bioscience Inc ANTI-CDCP1 ANTIBODIES
EP4215211A1 (en) 2020-09-02 2023-07-26 The University of Tokyo Tumor immune microenvironment regulator, and preventive, diagnostic or therapeutic use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5285899A (en) * 1998-07-21 2000-02-14 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
AU2001273363A1 (en) 2000-07-12 2002-01-21 General Instrument Corporation Method and apparatus for downloading objects via an inband channel with minimal subscriber impact
CA2429946A1 (en) * 2000-12-01 2002-07-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c

Also Published As

Publication number Publication date
ZA200406187B (en) 2006-06-28
EP1476468A2 (en) 2004-11-17
NZ534922A (en) 2008-07-31
KR20040077745A (ko) 2004-09-06
ATE407147T1 (de) 2008-09-15
US7727529B2 (en) 2010-06-01
WO2003064473A2 (en) 2003-08-07
DK1476468T3 (da) 2009-01-19
CA2474801C (en) 2012-03-20
EP1476468B9 (en) 2009-04-08
US20080241162A1 (en) 2008-10-02
US20050084845A1 (en) 2005-04-21
DE60323333D1 (de) 2008-10-16
EA200401081A1 (ru) 2005-10-27
WO2003064473A3 (en) 2003-12-24
JP2005531286A (ja) 2005-10-20
RU2004126238A (ru) 2005-04-20
ITRM20020049A0 (it) 2002-01-30
JP4287280B2 (ja) 2009-07-01
CN1856508A (zh) 2006-11-01
EA009861B1 (ru) 2008-04-28
KR101002791B1 (ko) 2010-12-21
ES2314179T3 (es) 2009-03-16
AU2003208000B2 (en) 2010-05-20
EP1476468B1 (en) 2008-09-03
CA2474801A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
ITRM20020049A1 (it) Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
EA201300022A1 (ru) Терапевтическое человеческое моноклональное антитело против il-1r1
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
NZ527283A (en) Modified antibodies and methods of use
AR069981A1 (es) Los "anticuerpo modificado geneticamente que reconocen cd138".
DK1383785T3 (da) Rekombinant tumorspecifikt antistof og anvendelse deraf
TR201900764T4 (tr) LAG-3 ve terapötik antikorlar içeren bileşimler ve bunların kanser tedavisinde kullanımı.
UA109633C2 (uk) Антитіло людини проти тканинного фактора
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
ATE364618T1 (de) Antikörper gegen das muc18-antigen
ECSP066379A (es) Anticuerpos rg1 y usos de los mismos
BR0312692A (pt) anticorpos selecionados e peptìdeos de duramicina que se ligam a fosfolipìdios aniÈnicos e aminofosfolipìdios e seus usos no tratamento de infecções virais e cáncer
ATE402192T1 (de) Anti-ccr4 antikörper und fragmente davon
CR8108A (es) Tratamiento con anticuerpos anti-vegf
TR200202253T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
MXPA05010830A (es) Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana.
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
YU55203A (sh) Konjugati jedinjenja specifičnog makrolida imunske ćelije sa anti-inflamatornim jedinjenjima, za poboljšano ćelijsko ciljanje u anti-inflamatornoj terapiji
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
EE05474B1 (et) Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud v„hivastaseks vaktsineerimiseks
MY141459A (en) Recombinant anti-idiotypic antibodies